Cocrystal Pharma, Inc. SEC Filings

Cocrystal Pharma, Inc. appointed Carol L. Brosgart, MD to its Board of Directors, effective August 12, 2026, and announced this in a press release dated August 17, 2026. The company describes itself as a clinical-stage biotechnology company developing antiviral therapeutics targeting noroviruses, influenza viruses, coronaviruses (including SARS-CoV-2), and hepatitis C viruses.

Dr. Brosgart brings several decades of experience in antiviral therapy, epidemiology, government service, and biopharmaceutical consulting, including key roles in the development and regulatory approval of antiviral therapies Viread® and Hepsera® at Gilead Sciences. Cocrystal’s leadership highlights her anticipated contributions to the clinical development of CDI-988 for norovirus and to the broader antiviral pipeline.

Cocrystal Pharma, Inc. is a clinical-stage antiviral drug developer focused on norovirus, influenza, coronavirus and HCV. For the six months ended June 30, 2026, it generated $330,000 of government contract revenue from a NIAID SBIR Phase I award and recorded a net loss of $5.46 million, wider than a year earlier, driven mainly by higher R&D spending on its CDI-988 norovirus/coronavirus program.

Cash and restricted cash were $2.24 million at June 30, 2026, versus $7.10 million at year-end 2025, with $4.86 million used in operating activities in the first half. Management and the auditor state that these conditions raise substantial doubt about the company’s ability to continue as a going concern, and the company expects its cash, including a subsequent $5.0 million equity investment by OPKO Health on July 31, 2026, will not fund operations for 12 months after the report date.

Pipeline updates include ongoing Phase 1b norovirus challenge work and FDA Fast Track designation for CDI-988, a pan-viral 3CL protease inhibitor, and continued development of influenza candidate CC-42344 and other broad-spectrum antivirals.

OPKO Health, Inc. and affiliates reported large ownership stakes in Cocrystal Pharma, Inc. common stock. OPKO beneficially owns 5,692,916 shares, representing 29.6% of Cocrystal’s common stock based on 19,263,200 shares outstanding as of August 6, 2026. On July 31, 2026, OPKO entered a Securities Purchase Agreement to buy 5,474,053 shares for $5,000,000, at $0.9134 per share, using working capital.

Phillip Frost, M.D. reports beneficial ownership of 2,786,412 shares (including common shares, warrants, options and restricted stock units), or 13.9% of the class. Frost Gamma Investments Trust reports 2,712,977 shares, or 13.6%, and Steven D. Rubin reports 2,724,860 shares, or 14.1%. Recent activity includes OPKO’s private purchase and Frost Gamma’s open‑market purchases totaling 85,000 shares at weighted average prices between $0.87 and $0.9898 per share.

A Stockholders Rights Agreement provides voting agreements and irrevocable proxies in favor of designated individuals and grants OPKO and other parties a right of first refusal to participate in future equity financings until Cocrystal has raised $70 million in cumulative equity financings. The stakes are described as held for investment, while OPKO and its principals may adjust their positions over time.

Phillip Frost, M.D. and Frost Gamma Investments Trust report updated ownership of Cocrystal Pharma, Inc. common stock. Dr. Frost is deemed to beneficially own 2,784,719 shares, representing 13.9% of the common stock, including direct holdings, shares held by the trust, vested options and warrants exercisable within 60 days.

Frost Gamma Investments Trust is reported as beneficially owning 2,712,977 shares, or 13.5% of the common stock, including common shares and warrants. On August 3 and 5, 2026, the reporting persons acquired 75,000 shares at $0.9412 and 10,000 shares at $0.9816, respectively, in open‑market purchases for investment purposes. Ownership percentages are based on 19,263,200 shares outstanding as of August 3, 2026, plus option and warrant shares issuable within 60 days.

Phillip Frost M.D., a director and 10% owner of Cocrystal Pharma, Inc., reported an indirect open-market purchase of 10,000 shares of Common Stock on August 5, 2026 at a weighted average price of $0.9816, with individual trade prices ranging from $0.972 to $0.9898, through Frost Gamma Investments Trust. After this purchase, the trust holds 1,993,551 shares indirectly, while Frost also reports 27,100 shares held directly, including shares issuable upon vesting of restricted stock units. Frost disclaims beneficial ownership of the trust-held securities and of securities owned by OPKO Health, Inc., except to the extent of any pecuniary interest, and the transaction was not reported as pursuant to a Rule 10b5-1 trading plan.

An entity associated with Cocrystal Pharma director and 10% owner Phillip Frost, M.D., Frost Gamma Investments Trust, purchased 75,000 shares of common stock on 2026-08-03 in an open-market or private transaction at a weighted average price of $0.9412 per share, with individual trade prices between $0.87 and $0.9499. Following this purchase, the trust holds 1,983,551 shares of Cocrystal Pharma common stock indirectly. Frost also has 27,100 shares held directly, which include shares issuable upon vesting of restricted stock units. Frost disclaims beneficial ownership of shares held by Frost Gamma Investments Trust and by OPKO Health, Inc., except to the extent of any pecuniary interest, and the transaction is not reported as made under a Rule 10b5-1 trading plan.

Cocrystal Pharma, Inc. entered into a Securities Purchase Agreement with longtime investor OPKO Health, Inc., under which Cocrystal sold 5,474,053 shares of common stock at $0.9134 per share, the Nasdaq Consolidated Bid Price on the closing date, generating $5.0 million in gross proceeds.

The unregistered private placement to OPKO, an accredited investor, relied on Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D, and included no warrants or other derivative securities. Dr. Phillip Frost, OPKO’s Chairman and CEO, is co-founder, director and principal stockholder of Cocrystal. The company plans to use net proceeds to advance its preclinical and clinical antiviral programs, including lead norovirus candidate CDI-988, and for general corporate purposes and working capital, and expects topline data from its Phase 1b norovirus trial by the end of the fourth quarter of 2026.

Cocrystal Pharma, Inc. held its 2026 Annual Meeting of Stockholders on July 14, 2026. Stockholders voted on electing five directors, ratifying the independent auditor for the fiscal year ending December 31, 2026, and a possible adjournment to solicit additional proxies if needed.

All five director nominees were elected, with votes for each ranging from 5,914,522 to 6,293,331, and 2,860,552 broker non-votes recorded for each nominee. Stockholders ratified Weinberg & Company as the independent registered public accounting firm, with 9,181,034 votes for, 174,923 against, and 10,587 abstentions. Because Proposals 1 and 2 received sufficient support, the adjournment proposal was moot.

Cocrystal Pharma, Inc. appointed James Sapirstein as Chief Executive Officer, effective immediately, under an employment offer letter. He will receive an initial annual base salary of $265,000 and an annual performance bonus targeted at 50% of base salary, tied to Board-set goals.

Sapirstein was granted 10-year stock options to purchase 235,000 shares at an exercise price of $1.05, vesting in four equal annual installments beginning June 3, 2027, with accelerated vesting upon a Change in Control or certain terminations. The Offer Letter also contemplates a potential additional grant of options to purchase another 235,000 shares six months after his start date, subject to performance targets and approvals. He replaces prior Co-CEOs Sam Lee and James Martin, who continue as President/Chief Scientific Officer and Chief Financial Officer, respectively.